NCT07713732 TLN-499 Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07713732 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07713732 is a hot trial to watch
Recurrent Lung Small Cell Carcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07713732 is notable because it evaluates TLN-499 in a Phase 1 design sponsored by Treeline Biosciences, Inc.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07713732 |
| Official title | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors |
| Phase / status | Phase 1 / Not yet recruiting |
| Intervention | TLN-499 |
| Sponsor | Treeline Biosciences, Inc. |
| Geography | Australia |
| Enrollment | [object Object] |
| Primary endpoint | Incidence of Dose-Limiting Toxicities (DLTs) |
| Endpoint time frame | First 35 days of treatment |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across Australia shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Incidence of Dose-Limiting Toxicities (DLTs) (First 35 days of treatment) — Number of patients experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-499
- Incidence of Adverse Events and Serious Adverse Events (Up to approximately 2 years) — Incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and deaths.
- Overall Response Rate (ORR) (Up to approximately 2 years) — ORR assessed according to RECIST v1.1 (or mRECIST for mesothelioma)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: TLN-499 is indexed as Targeted protein degraders, with target Bcl-xl, mechanism Bcl-xl degraders, and global highest development status Phase 1.
Company & Deal Intelligence MCP profile: Treeline Biosciences, Inc. is resolved to a normalized organization record in MIDDLESEX COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07713732 provides a focused lens on Recurrent Lung Small Cell Carcinoma development. Its value will be determined by whether TLN-499 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
